A5085704403- Influenza Virus Research Studies
- Respiratory viral infections research
- Immune Response and Inflammation
- SARS-CoV-2 and COVID-19 Research
- Animal Disease Management and Epidemiology
- Immunotherapy and Immune Responses
- Monoclonal and Polyclonal Antibodies Research
- vaccines and immunoinformatics approaches
- Viral Infections and Vectors
- Viral gastroenteritis research and epidemiology
- Immune Cell Function and Interaction
- Animal Virus Infections Studies
- COVID-19 Clinical Research Studies
- Thermal Regulation in Medicine
- Tuberculosis Research and Epidemiology
- Herpesvirus Infections and Treatments
- T-cell and B-cell Immunology
- Hepatitis B Virus Studies
- interferon and immune responses
- Vaccine Coverage and Hesitancy
- SARS-CoV-2 detection and testing
- Pharmacological Effects and Assays
- Escherichia coli research studies
- COVID-19 epidemiological studies
- Bacteriophages and microbial interactions
Institute of Experimental Medicine
2014-2024
Czech Academy of Sciences, Institute of Experimental Medicine
2015-2022
Russian Academy of Sciences
2011
Introduction Live attenuated influenza vaccines (LAIVs) are being developed to protect humans against future epidemics and pandemics. This study describes the results of a double–blinded randomized placebo–controlled phase I clinical trial cold–adapted temperature sensitive H7N3 live vaccine candidate in healthy seronegative adults. Objective The goal was evaluate safety, tolerability, immunogenicity potential shedding transmission LAIV H7 avian virus pandemic potential. Methods Findings Two...
The emergence of the new coronavirus SARS-CoV-2 in late 2019 led to global pandemic COVID-19, causing a profound socioeconomic crisis. Adequate diagnostic tools need be developed control ongoing spread infection. Virus-specific humoral immunity COVID-19 patients and those vaccinated with specific vaccines has been characterized numerous studies, mainly using Spike protein-based serology tests. However, protein specifically its receptor-binding domain (RBD) are mutation-prone, suggesting...
Abstract Objective Our studies aimed to evaluate in clinical trials the safety and immunogenicity of an H5 live influenza vaccine candidate obtained using classical reassortment techniques from a low pathogenicity avian (LPAI) A/Duck/Potsdam/1402‐6/86(H5N2) virus cold‐adapted ( ca ) donor strain A/Leningrad/134/17/57(H2N2). Methods During Phase I–II trials, volunteers received intranasally two doses reassortant A/17/Duck/Potsdam/86/92 (H5N2) 21 days apart. Clinical examination all vaccinees...
During the past decade, a number of H5 subtype influenza vaccines have been developed and tested in clinical trials, but most them induced poor serum antibody responses prompting evaluation novel vaccination approaches. One promising ones is "prime-boost" strategy, which could result induction prompt robust immune to booster vaccine following priming with homologous or heterologous strains. In our study we evaluated immunogenicity an adjuvanted A(H5N1) inactivated (IIV) healthy adult...
Cellular immune responses of both CD4 and CD8 memory/effector T cells were evaluated in healthy young adults who received two doses live attenuated influenza A (H5N2) vaccine. The vaccine was developed by reassortment nonpathogenic avian A/Duck/Potsdam/1402-6/68 cold-adapted A/Leningrad/134/17/57 (H2N2) viruses. T-cell measured standard methods intracellular cytokine staining gamma interferon (IFN-γ)-producing a novel recognition antigen-presenting protein capture (TRAP) assay based on the...
H2N2 influenza viruses have not circulated in the human population since 1968, but they are still being regularly detected animal reservoir, suggesting their high pandemic potential. To prepare for a possible pandemic, number of vaccine candidates been generated and tested preclinical clinical studies. Here we describe results randomized, double-blind placebo-controlled phase 1 trial an live attenuated (LAIV) candidate prepared from virus isolated 1966. The was safe well-tolerated by healthy...
The development of universal influenza vaccines has been a priority for more than 20 years. We conducted preclinical study in ferrets two sets live attenuated (LAIVs) expressing chimeric hemagglutinin (cHA). These contained the HA stalk domain from H1N1pdm09 virus but had antigenically unrelated globular head domains avian viruses H5N1, H8N4 and H9N2. viral nucleoproteins (NPs) LAIV candidates were different sources: one set NP A/Leningrad/17 master donor (MDV), while other this gene was...
Since conserved viral proteins of influenza virus, such as nucleoprotein (NP) and matrix 1 protein, are the main targets for virus-specific CD8+ cytotoxic T-lymphocytes (CTLs), we hypothesized that introduction NP gene wild-type virus into genome vaccine reassortants could lead to better immunogenicity afford protection. This paper describes in vitro vivo preclinical studies two new pandemic H1N1 live attenuated (LAIV) candidates. One had hemagglutinin (HA) neuraminidase (NA) genes from...
The majority of seasonal influenza vaccines are trivalent, containing two A virus strains (H1N1 and H3N2) one B strain. co-circulation distinct lineages viruses can lead to mismatch between the strain recommended for trivalent vaccine circulating virus. This has led some manufacturers produce quadrivalent from each lineage in addition H1N1 H3N2 strains. However, it is also important know whether a single provide cross-protectivity against antigenically lineage. aim this study was assess...
Influenza and SARS-CoV-2 viruses are two highly variable pathogens. We have developed a candidate bivalent live vaccine based on the strain of licensed A/Leningrad/17-based cold-adapted attenuated influenza (LAIV) H3N2 subtype, which expressed immunogenic T-cell epitopes. A cassette encoding fragments S N proteins was inserted into NA gene using P2A autocleavage site. In this study, we present results preclinical evaluation in non-human primate model.
The development of an influenza vaccine with broad protection and durability remains attractive idea due to the high mutation rate virus. An extracellular domain Matrix 2 protein (M2e) is among most target for universal owing its conservancy rate. Here, we generated two recombinant live attenuated (LAIV) candidates encoding four M2e epitopes representing consensus sequences human, avian swine viruses, studied them in a preclinical ferret model. Both LAIV+4M2e viruses induced higher levels...
Background: Currently, the immunogenicity of influenza vaccines is assessed by detecting an increase hemagglutination inhibition (HI) antibodies. As neuraminidase (NA)-based immunity may be significant in protecting against infection, detection inhibiting (NI) antibodies improve assessment vaccines. Methods: We investigated immune response to NA people after immunization with live (LAIVs). A number A/H7NX or A/H6NX viruses were used detect NI antibodies, using enzyme-linked lectin assay...
Please cite this paper as: Petukhova et al . (2011) B‐ and T‐cell memory elicited by a seasonal live attenuated reassortant influenza vaccine: assessment of local antibody avidity virus‐specific T‐cells using trogocytosis‐based method. Influenza Other Respiratory Viruses DOI: 10.1111/j.1750‐2659.2011.00279.x. Purpose The main purpose vaccination is to generate immunological providing enhanced immune responses against infectious pathogens. standard most commonly used assay for vaccine...
Background. Currently, two genetic lineages of influenza B virus, B/Victoria and B/Yamagata, are cocirculating in humans various countries. This situation has raised a question regarding the possibility cross-protection between components live attenuated vaccine (LAIV) belonging to different lineages. study aimed assess naïve ferrets potential protective activity monovalent B-LAIVs against challenge with homologous heterologous wild-type (WT) viruses. Methods. Groups seronegative female 5-6...
Influenza H7N9 virus is a potentially pandemic subtype to which most people are immunologically naïve. To be better prepared for the potential occurrence of an pandemic, in 2017 World Health Organization recommended developing candidate vaccine viruses from two new viruses, A/Guangdong/17SF003/2016 (A/GD) and A/Hong Kong/125/2017 (A/HK). This report describes development live attenuated influenza (LAIV) candidates against A/GD A/HK study their safety immunogenicity ferret model order choose...
Pre-existing antibodies to influenza virus neuraminidase may provide protection against infection viruses containing novel hemagglutinin (HA). The aim of our study was evaluate serum neuraminidase-inhibiting (NI) А/California/07/2009(H1N1) [H1N1/2009pdm] and А/New Caledonia/20/1999(H1N1) [H1N1/1999] in relation with the age participants hemagglutination-inhibition (HI) antibody levels. Anti-H1N1/2009pdm anti-H1N1/1999 levels were measured total 219 samples from Russian healthy peoples...
This study describes a double-blind randomized placebo-controlled phase I clinical trial in healthy adults of new potential pandemic H7N9 live attenuated influenza vaccine (LAIV) based on the human virus Yangtze River Delta hemagglutinin lineage (ClinicalTrials.gov Identifier: NCT03739229). Two doses LAIV or placebo were administered intranasally to 30 and 10 subjects, respectively. The was well-tolerated not associated with increased rates adverse events any serious events. Vaccine detected...
Influenza outbreaks caused by A/H7N9 viruses have occurred since 2013. After 2016, influenza underwent evolutionary changes. In this study, we examined the antigenic properties of neuraminidase (NA) as part a live vaccine (LAIV). It was shown that inhibiting (NI) antibodies obtained after A/Anhui/1/2013(H7N9)-based LAIV vaccination did not inhibit A/Hong Kong/125/2017(H7N9) NA and vice versa. The Kong/125/2017(H7N9)-based elicited higher levels NI compared to two doses. Thelow degree...
Background/Objectives: Influenza viruses and SARS-CoV-2 are currently cocirculating with similar seasonality, both pathogens characterized by a high mutational rate which results in reduced vaccine effectiveness thus requires regular updating of compositions. Vaccine formulations combining seasonal influenza strains can be considered promising cost-effective tools for protection against infections. Methods: We used licensed trivalent live attenuated (3×LAIV) as basis the development modified...